GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!On April 19, 2022, Innovative Cellular Therapeutics (ICT) company from Shanghai, China receives FDA Fast Track Designation for GCC19CART. GCC19CART is a CAR-T cell therapy based on ICT's unique CoupledCAR® technology...
Detailed information

ROR1, an Emerging Target for Tumor ImmunotherapyROR1 has emerged as a key target, with multiple pharmaceutical companies advancing ROR1-targeted drugs into clinical trials. Recently, Merck & Co. acquired Zilovertamab Vedotin (MK-2140) for $2.75 billion, and its clinic...
Detailed information

TFPI: a Natural Anticoagulant Protein, Future Therapies for HemophiliaPfizer announced that its TFPI antibody, Marstacimab (brand name Hympavzi), has been approved by the FDA. This marks a significant advance in hemophilia treatment. Hympavzi is the first FDA-approved TFPI antibody and pro...
Detailed information

TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!AstraZeneca and Neurimmune Therapeutics have signed an agreement on Mar. 1, 2022, contributing about $700 million cooperation on NI006 clinical research. NI006 is a transthyretin (TTR) targeting modulator for rare diseas...
Detailed information

DT3C, a Powerful Tool for ADC Drug Internalization In VitroHighlight 1. Can simulate ADC drug function in vitro. 2. Simple preparation of mAb–DT3C complexes. 3. Can combine with mAbs from multiple sources. 4. Antibody internaliza...
Detailed information

ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!On January 28, 2022, the FDA approved the first bispecific antibody Vabysmo (Ang-2 x VEGF-A) for eye, to treat two leading causes of vision loss--wet age-related macular degeneration (AMD) and diabetic macular edema (DME...
Detailed information

GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) has emerged as a promising therapeutic target, garnering significant attention in the field of oncology and immunotherapy. Particularly in the treatment of mul...
Detailed information

CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy！BioLineRx Ltd presently has completed a successful pre-New Drug Application (NDA) meeting regarding a chemokine receptor CXCR4 antagonist (Motixafortide), from a report on January 18, 2022. In particular, the biopharmace...
Detailed information

The Collection of Progress of Anti-GPCR Antibody DrugsAs mentioned in the article entitled "G protein-Coupled Receptor - Targets for Drug Therapy", GPCRs is an important drug target, and currently about 40% of the marketed drugs are designed based on GPCRs. About 34% of dru...
Detailed information

Chemokine Receptor CCR4: the Key Role of CCR4+Treg Cells in Cancer ImmunotherapyOn Jan 17, 2022, Nature Reviews Clinical Oncology (IF: 66.675) published a review entitled "Harnessing cytokines and chemokines for cancer therapy" [1]. In this article, the authors conclude the high potential of targeti...
Detailed information